Archive WILEX Ad-hoc- and Press Releases 2006

ENGLISH DEUTSCH

Selected press releases of the former years can be found here.

15 December 2006
AH: WILEX receives approval for clinical Phase II trial with oral WX-671 in pancreatic cancer

PR: WILEX receives approval for clinical Phase II trial with oral WX-671 in pancreatic cancer
13 December 2006
PR: WILEX enters into manufacturing and distribution agreement with IBA Molecular for the upcoming pivotal registration trial with CA9-SCAN
10 November 2006
AH: WILEX shares successfully placed at EUR 13.80

PR: WILEX shares successfully placed at EUR 13.80
06 November 2006
AH: Price range for WILEX shares set at EUR 13.80 to EUR 15.80

PR: Price range for WILEX shares set at EUR 13.80 to EUR 15.80
24 October 2006
PR: WILEX announces details of IPO
20 October 2006
PR: New antibody based diagnostic imaging agent demonstrates 100 % positive predictive accuracy in feasibility study
16 October 2006
PR: WILEX successfully completes Phase II study with RENCAREX®* in combination with Interferon
11 October 2006
PR: WILEX Plans IPO
07 August 2006
PR: WILEX completes Phase I program with anti-cancer drug WX-671 in healthy volunteers and holds clinical Phase Ib study in cancer patients now
31 July 2006
PR: WILEX completes two Phase Ib studies with anti-cancer drug WX-UK1 in cancer patients

19 June 2006
PR: Change in Senior Management of WILEX AG
01 March 2006
PR: WILEX Appoints Members to its Medical Advisory Board for RENCAREX®* and the Phase III ARISER Study
Seite gelesen: 239 | Heute: 2